To explore the potential of in vivo CAR T-cell therapy for treating autoimmune diseases, addressing the limitations of current ex vivo approaches.
Approach:
Ex Vivo CAR T-cell Therapy Challenges: Current CAR T-cell therapies are effective for hematologic malignancies but face high costs, complex manufacturing, and logistical challenges.
In Vivo CAR T-cell Therapy Mechanism: In vivo CAR T-cell therapy aims to deliver mRNA instructions to T cells to produce B-cell-targeting CARs, potentially treating autoimmune diseases.
Technological Advancements: Modified lipid nanoparticles (LNP) are being developed to deliver mRNA specifically to T cells, enhancing safety and efficacy.
Key Findings:
Ex vivo CAR T-cell therapy is costly and logistically complex, limiting its application in autoimmune diseases.
In vivo approaches using LNP can improve the delivery of CAR T-cell therapies, enhancing specificity and reducing side effects.
DARPins show promise as a more effective targeting mechanism for LNP compared to traditional monoclonal antibodies.
Interpretation:
Limitations:
Current studies are primarily preclinical and conducted in mouse models.
The safety and efficacy of in vivo CAR T-cell therapies in humans remain to be fully established.
The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.
